Ethics and the Business of Bioscience

Portada
Stanford University Press, 2004 - 534 páginas
Businesses that produce bioscience products gene tests and therapies, pharmaceuticals, vaccines, and medical devices are regularly confronted with ethical issues concerning these technologies. Conflicts exist between those who support advancements in bioscience and those who fear the consequences of unfettered scientific license. As the debate surrounding bioscience grows, it will be increasingly important for business managers to consider the larger consequences of their work.

This groundbreaking book follows industry research, development, and marketing of medical and bioscience products across a variety of fields, including biotechnology, pharmaceuticals, and bio-agriculture. Compelling and current case studies highlight the ethical decisions business managers frequently face. With the increasing visibility and public expectation placed on businesses in this sector, managers need to understand the ethical and social issues. This book addresses that need and provides a framework for incorporating ethical analysis in business decision making.

 

Índice

Acknowledgments
xi
Introduction 3
xviii
4
xviii
Benefits of addressing ethical and social issues
13
Ethics and Business Activity 233
25
Moral systems
31
Kantian ethics rights and duties
39
Justice and fairness
46
IndustrySponsored Clinical Research and the Use of Placebo Controls
195
Changing views on placebo controls
202
8
227
Mitigation of Harm to Subjects Injured in Clinical Research
235
Industry research practice
242
HIV transmission trial in Uganda
282
VaxGen Inc fighting the AIDS epidemic
288
ΙΟ
329

Compensatory justice
55
3
65
Analysis of case study
84
Rights analysis
94
Ethical reasoning conclusions ΙΟΙ
101
Research Ethics
106
Animal research
119
Industry Regulation and the Product Approval Process
129
Clinical trials process
137
Medical device regulation
143
6
151
Changes in industryacademic relationships
159
Myriad and OncorMed and the marketing of
337
II
363
Access to Medical Products
377
Accelerated drug approval
384
Mercks U S managed distribution program for
391
12
414
Advertising Prescription Drugs Directly to Patients
427
DTC prescription drug advertising expenditures
434
Zenecas directtoconsumer advertising
443
Index
519
Página de créditos

Otras ediciones - Ver todo

Términos y frases comunes

Referencias a este libro

The Biology of Cancer
Janice Ann Gabriel
Vista previa restringida - 2007

Sobre el autor (2004)

Margaret L. Eaton is a Senior Research Scholar at the Stanford Center for Biomedical Ethics and a Lecturer in the Stanford Graduate School of Business. She is a founding member of the Bioscience Business Ethics Center, Keck Graduate Institute, Claremont Colleges.

Información bibliográfica